Aquestive Therapeutics appoints Rich Daly to board of directors

By Public Technologies
  • Aquestive Therapeutics appointed Rich Daly to its board, effective Oct. 14, 2026.
  • Daly brings more than 30 years of biopharma leadership, including commercial and operating roles at AstraZeneca, Takeda, Catalyst.
  • The board will have eight directors following the appointment.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aquestive Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609290700PRIMZONEFULLFEED9835487) on September 29, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk